Gastroenterology

Do GERD and asthma represent one-two punch for children?

Yesterday

Children with gastro-oesophageal reflux disease (GERD) are at heightened risk of developing asthma, and those with asthma are prone to develop GERD, according to a study, which suggests that the two conditions have a bidirectional relationship.

Prophylactic clipping of large, proximal lesions cuts postpolypectomy bleeding

6 days ago

Routine prophylactic clipping after polypectomy may not decrease postoperative bleeding, a new meta-analysis has found. However, it may reduce bleeding after the excision of large proximal lesions.

From the throat to the gut: Essential learnings for physicians

10 Mar 2020

RB Health is committed to support healthcare quality improvement through CME activities that help physicians stay updated with the latest developments in medicine. At the RB symposium held in Kuala Lumpur, two distinguished speakers gave their insights into the management of acid reflux and sore throat – two of the most common reasons for patients to visit their doctors.

Vonoprazan: A new era in the treatment of acid-related diseases

26 Nov 2019

At the recent Takeda Malaysia Vocinti® (vonoprazan) launch, held in conjunction with the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology - GUT 2019 at Shangri-La Kuala Lumpur, Professor Akihito spoke about vonoprazan’s merits as an alternative to conventional proton pump inhibitors.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).

PyloBalance as an adjunct therapy in the treatment of H. pylori infections

17 Jul 2019

All Helicobacters are urease-positive, able to convert aminoacids and urea into ammonia to neutralize stomach acid, andhighly mobile – characteristics that help them invade the mucosallayer to evade the body’s immune response. Helicobacter pylori(H. pylori) is linked to peptic ulcer disease, chronic gastritis,gastric mucosa-associated lymphoid tissue lymphoma, andearly gastric cancer. The infection rate of H. pylori is over 80% indeveloping countries and 20–50% in industrialized nations, withover 4.4 billion people testing positive for the bacteria in 2015.1,2

Vonoprazan tops lansoprazole in reducing erosive oesophagitis recurrence in Asians

Roshini Claire Anthony, 19 Jun 2020

A once-daily maintenance dose of vonoprazan 10 mg or 20 mg may be a suitable substitute to lansoprazole in reducing the risk of erosive oesophagitis (EE) recurrence, according to a phase III noninferiority study presented at DDW 2020.

Plecanatide favourable for older individuals with CIC, IBS-C

Audrey Abella, 16 Jun 2020

The guanylate cyclase-C receptor agonist plecanatide is effective and well-tolerated by older individuals (≥65 years) with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), results of a post hoc analysis presented at DDW 2020 has shown.

Rifaximin effective in treatment unresponsive IBS-D

Roshini Claire Anthony, 15 Jun 2020

Patients with irritable bowel syndrome with diarrhoea (IBS-D) who have not responded to other medications may benefit from rifaximin, post hoc analyses of the TARGET 3* trial showed.

SC vedolizumab improves outcomes in patients with Crohn’s disease

Audrey Abella, 12 Jun 2020

Maintenance therapy with a new subcutaneous (SC) formulation of the monoclonal antibody vedolizumab led to improvements in patient-reported outcomes (PROs) in patients with moderate-to-severe active Crohn’s disease (CD) compared with placebo, interim results of the phase III VISIBLE 2 study has shown.

Budesonide oral suspension improves endoscopic outcomes in eosinophilic oesophagitis

Audrey Abella, 08 Jun 2020

Budesonide oral suspension (BOS), a liquid formulation of a topical corticosteroid, improved endoscopic outcomes in patients with eosinophilic oesophagitis (EoE), a phase III trial has shown.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!